United Therapeutics

Bill Stewart, a 54-year-old New Hampshire man, successfully received a genetically engineered pig kidney transplant on June 14 and no longer requires dialysis after being discharged from Massachusetts General Hospital.

United Therapeutics announced that its TETON-2 phase 3 study of nebulized Tyvaso (treprostinil) met its primary endpoint, demonstrating a statistically significant 95.6 mL improvement in absolute forced vital capacity versus placebo in idiopathic pulmonary fibrosis patients.

Bavarian Nordic announced the sale of its Priority Review Voucher for $160 million, awarded following FDA approval of its chikungunya vaccine VIMKUNYA in February 2025.

Six pharmaceutical facilities received category awards for innovation, operations, and social impact at the 2025 ISPE Europe Annual Conference, marking the 20th anniversary of the prestigious FOYA program.

• AstraZeneca has inaugurated a new $300 million cell therapy manufacturing facility in Rockville, Maryland, designed to produce CAR-T cell therapies for cancer treatment and create over 150 specialized jobs. • The 84,000-square-foot facility is part of AstraZeneca's broader $3.5 billion investment in U.S. research and manufacturing, strengthening Montgomery County's position as a leading bio-life sciences hub. • The project received combined support of $600,000 from Montgomery County and Maryland state agencies, along with job creation tax credits and expedited permitting to accelerate the facility's completion.

A U.S. District Court has dismissed a legal dispute filed by United Therapeutics against Liquidia, marking a significant development in ongoing patent litigation between the two pharmaceutical companies.

U.S. District Court Judge Kelly dismissed United Therapeutics' cross-claim challenging Liquidia's NDA amendment for YUTREPIA, ruling that UTHR failed to establish standing.

Priority Review Vouchers (PRVs) have surged in value to $150-158 million in recent months, up from the typical $100 million, following Congress's failure to reauthorize the rare pediatric disease program.

The FDA has approved clinical trials for two companies, United Therapeutics and eGenesis, to transplant genetically modified pig kidneys into humans with kidney failure.

United Therapeutics received FDA clearance for its IND application to begin clinical trials for UKidney, a gene-edited pig kidney, marking a significant step in xenotransplantation.